Clinical Trial


To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)


Brief description

This will be a multicenter, 52-week, open-label study designed to assess the safety and tolerability of an oral aripiprazole/escitalopram combination therapy in outpatients with major depressive disorder (MDD). Enrollment into the study will be from eligible subjects who have completed participation in Protocol 31-08-255, 31-08-256, or 31-08-263 ("rollover" subjects).

Keywords

  •   Major Depressive Disorder (MDD)

Sponsored By

Otsuka Pharmaceutical Development & Commercialization, Inc.

Unique Study ID

NCT01123707

Investigators and Research Sites Near You - Found( 3 )

No Investigator Listed

AstraZeneca
Catania, Italy
Distance from Current Trial is 0 miles

No Investigator Listed

University of Catania
95124, Catania, CT, Italy
Distance from Current Trial is 0 miles

No Investigator Listed

Chiesi Farmaceutici S.p.A.
Catania, Italy
Distance from Current Trial is 0 miles
View All